Precision Medicine Considerations in Melanoma: Identifying Patients and Optimizing Genetic, Molecular Testing

Source: AJMC, March 2022

Panelists reviewed the latest advancements in clinical testing for melanoma, targeted therapy implications, and strategies for patient selection at a session on genetic and molecular testing at the 2022 American Academy of Dermatology (AAD) Annual Meeting.

Genetic and molecular testing may lead to earlier detection of melanoma and potentially other cancers, as well as guide decision-making on use of immunotherapies and targeted therapies. But deciding which tests to use and who would benefit from such testing warrants consideration among dermatologists.

Jeffrey P. North, MD, FAAD, managing director and associate professor of Pathology and Dermatology, University of California San Francisco, discussed the current availability of molecular tests in dermapathology and how they can help assess difficult biopsies during a Saturday session at a 2022 American Academy of Dermatology (AAD) Annual Meeting.